Table III.
Risk variants for anthracycline-related CHF
| Gene | SNP rs-ID | Chr. | Position* | At risk genotype | Cases (n=77) | Controls (n=178) | OR** (95% CI) | FDR-adjusted P -Value |
|---|---|---|---|---|---|---|---|---|
| AGT | rs699 | 1 | 230845794 | GA/AA | 54 (70.1) | 122 (68.5) | 1.15 (0.57–2.30) | 0.88 |
| AGTR1 | rs5186 | 3 | 148459988 | CA/AA | 26 (33.7) | 79 (44.4) | 0.68 (0.37–1.25) | 0.88 |
| ADRB2 | rs1042713 | 5 | 148206440 | GG | 31 (40.3) | 54 (30.3) | 0.60 (0.31–1.20) | 0.35 |
| HFE | rs1800562 | 6 | 26093141 | GA/AA | 2 (2.6) | 15 (8.4) | 0.30 (0.05–1.23) | 0.28 |
| rs1799945 | 6 | 26091179 | CG/GG | 23 (29.9) | 27 (15.2) | 2.58 (1.27–5.20) | 0.03 | |
| SOD2 | rs4880 | 6 | 160113872 | GA/AA | 65 (84.4) | 132 (74.2) | 1.79 (0.90–3.38) | 0.28 |
| ABCC2 | rs8187710 | 10 | 101611294 | GA/AA | 16 (20.8) | 13 (7.3) | 5.22 (1.92–13.84) | 0.02 |
| NQO1 | rs1800566 | 16 | 69745145 | CT/CC | 73 (94.8) | 168 (94.4) | 0.88 (0.23–3.42) | 0.88 |
| CYBA | rs4673 | 16 | 88713236 | GA/AA | 39 (50.6) | 92 (51.7) | 1.29 (0.72–2.44) | 0.65 |
| ACE | rs4343 | 17 | 61566031 | AG/GG | 57 (74.0) | 122 (68.6) | 1.28 (0.67–2.45) | 0.72 |
| CBR1 | rs9024 | 21 | 37445313 | GG | 60 (77.9) | 129 (72.4) | 1.51 (0.76–3.03) | 0.46 |
| CBR3 | rs1056892 | 21 | 37518706 | GG | 35 (45.5) | 74 (41.6) | 1.08 (0.59–1.87) | 0.88 |
| NCF4 | rs1883112 | 22 | 37256846 | AA | 18 (23.3) | 36 (20.2) | 1.06 (0.54–2.13) | 0.88 |
| RAC2 | rs13058338 | 22 | 37632770 | TA/AA | 42 (54.5) | 58 (32.6) | 2.61 (1.46–4.69) | 0.02 |
*
Chromosomal position in the GRCh37.p5
**
Univariate model
CHF, congestive heart failure; SNP, single nucleotide polymorphism;rs ID, rs identification; Chr, chromosome; OR, odds ratio; 95% CI, 95% confidence interval; FDR, false discovery rate.